Citations

Mayo Clinic

Showing 10 of 108551 citations.

Approach to the Patient With Bilateral Adrenal Masses
Vassiliadi, Dimitra A. , Delivanis, Danae Anastasia, Papalou, Olga , Tsagarakis, Stylianos , Vassiliadi, Dimitra A , Delivanis, Danae A.

The Journal of Clinical Endocrinology & Metabolism | March 13, 2024 | Volume: 109 | Issue: 8 | Pages: 2136-2148

10.1210/clinem/dgae164 | PMID 38478374 Get It

Abstract Bilateral adrenal masses, increasingly encountered in clinical practice, manifest across diverse contexts, including incidental discovery, malignancy staging, and targeted imaging after hormonal diagnosis of adrenal disorders. The spectrum encompasses various pathologies, such as cortical adenomas, macronodular adrenal disease, pheochromocytomas, myelolipomas, infiltrative disorders, and primary and secondary malignancies. Notably, not all masses in both adrenal glands necessarily share the same etiology, often exhibiting diverse causes. Recently, the European Society of Endocrinology and the European Network for the Study of Adrenal Tumors updated guidelines, introduced a 4-option schema based on imaging, aiding in targeted hormonal testing and management. This “Approach to the Patient” review delves into the latest advancements in imaging, biochemical, and genetic approaches for the diagnostic and management nuances of bilateral adrenal masses. It provides insights and a contemporary framework for navigating the complexities associated with this clinical entity.
A Rare Presentation of Occipital Dermoid Cyst with Intracranial Extension and Secondary Infection: Case Report and Follow-Up
Li, Guyu , Kim, J. H., Garcia, Matthew, Reyes-McChesney, Ivy, Hanna, Ashley, Bhalala, Utpal , Kim, Jaechoon

Journal of Neurological Surgery Reports | March 13, 2024 | Volume: 85 | Issue: 02 | Pages: e39-e42

10.1055/a-2287-2108 | PMID 38596231 Get It

Abstract Craniofacial dermoid cysts are congenital anomalies that rarely have intracranial extension and can be associated with other anomalies. Common sites of these lesions are the lateral brow and parietal scalp. Presentation of the dermoid cyst in the occipital region with intracranial extension is extremely rare. We report a 2-year-old female with a presentation of an occipital dermoid cyst with intracranial extension and secondary cerebellar abscess. This case highlights the rarity of the presentation of an occipital dermoid cyst with intracranial extension and secondary infection and the importance of early imaging for suspected dermoid cysts in the occipital region for identification of intracranial extension.
Palliative and End-of-Life Care in Hematologic Malignancies: Progress and Opportunities
Tsang, Mazie , LeBlanc, Thomas W. , Leblanc, Thomas , Tsang, Mazie

JCO Oncology Practice | March 13, 2024 | Volume: 20 | Issue: 6 | Pages: 739-741

10.1200/op.24.00081 | PMID 38478797 Get It

@JCOOP_ASCO editorial on unique needs of end-of-life care for different blood cancers discusses: #pallheme improves QOL but less utilized in cancers. Contextualize Weisse et al study. More #pallheme research needed for lymphoma and myeloma in era of cell therapy
Next-Generation Multitarget Stool DNA Test for Colorectal Cancer Screening
Imperiale, Thomas F. , Zella, Julia, Olson, Marilyn C. , Statz, Sandi, Garces, Jorge , Lavin, Philip T. , Aguilar, Humberto , Brinberg, Don, Berkelhammer, Charles , Porter, Kyle, Gagrat, Zubin D. , Porter, Kyle M. , Kisiel, John B. , Limburg, Paul J.

New England Journal of Medicine | March 13, 2024 | Volume: 390 | Issue: 11 | Pages: 984-993

10.1056/nejmoa2310336 | PMID 38477986 Get It

Mass spectrometry-based proteomic analysis to characterize cisplatin induced early signaling events in head and neck squamous cell carcinoma
Ghose, Vivek, Munshi, Srijon, Bhat, Firdous Ahmad , Nanjappa, Vishalakshi , Bhat, Firdous A., Nanjappa, Vishalakshi , Jain, Ankit , Dey, Gourav

Molecular & Cellular Oncology | March 13, 2024 | Volume: 11 | Issue: 1 | Pages: No page available

10.1080/23723556.2024.2328873 | PMID 38487372 Get It

Oncocytic Thyroid Carcinoma Is a Distinct Clinical Entity
Boucai, Laura , Shonka, David C. , Chintakuntlawar, Ashish V.

Clinical Thyroidology® | March 13, 2024 | Volume: 36 | Issue: 3 | Pages: 83-86

10.1089/ct.2024;36.83-86 Get It

Retrospective Review of Positive Newborn Screening Results for Isovaleric Acidemia and Development of a Strategy to Improve the Efficacy of Newborn Screening in the UK
Carling, Rachel S. , Hedgethorne, Katy, Chakrapani, Anupam , Flynn, Nick , Greenfield, Toby, Moat, Stuart J. , Ssali, Joshua, Shakespeare, Lynette , Taj, Nazia, Wu, Teresa Hoi-Yee , Ghosh, Arunabha , Lemonde, Hugh , Pierre, Germaine, Sharrard, Mark, Sreekantam, Sreevidya, Bonham, James R. , Flynn, Nick , Moat, Stuart J , Wu, Teresa H Y , Bonham, James R , Hall, Patricia , Anderson, Mark

International Journal of Neonatal Screening | March 13, 2024 | Volume: 10 | Issue: 1 | Pages: 24

10.3390/ijns10010024 | PMID 38535128 Get It

Since the UK commenced newborn screening for isovaleric acidemia in 2015, changes in prescribing have increased the incidence of false positive (FP) results due to pivaloylcarnitine. A review of screening results between 2015 and 2022 identified 24 true positive (TP) and 84 FP cases, with pivalate interference confirmed in 76/84. Initial C5 carnitine (C5C) did not discriminate between FP and TP with median (range) C5C of 2.9 (2.0–9.6) and 4.0 (1.8–>70) µmol/L, respectively, and neither did Precision Newborn Screening via Collaborative Laboratory Integrated Reports (CLIR), which identified only 1/47 FP cases. However, among the TP cases, disease severity showed a correlation with initial C5C in ‘asymptomatic’ individuals (n = 17), demonstrating a median (range) C5C of 3.0 (1.8–7.1) whilst ‘clinically affected’ patients (n = 7), showed a median (range) C5C of 13.9 (7.7–70) µmol/L. These findings allowed the introduction of dual cut-off values into the screening algorithm to reduce the incidence of FPs, with initial C5C results ≥ 5 µmol/L triggering urgent referral, and those >2.0 and <5.0 µmol/L prompting second-tier C5-isobar testing. This will avoid delayed referral in babies at particular risk whilst reducing the FP rate for the remainder.
A Phase I Study of the Oral Dual-Acting Pan-PI3K/mTOR Inhibitor Bimiralisib in Patients with Advanced Solid Tumors
Jankú, Filip , Choong, Grace M. , Opyrchal, Mateusz , Dowlati, Afshin , Hierro, Cinta , Wicki, Andreas , Blagden, Sarah P. , Yin, Jun , Müller, Hélène, Cmiljanović, Nataša, Cmiljanović, Vladimir, Adjei, Alex A. , Wicki, Andreas , Opyrchal, Mateusz , Rodon, Jordi , Forster, Martin D , Reid, Joel M. , Muller, Helene

Cancers | March 13, 2024 | Volume: 16 | Issue: 6 | Pages: 1137

10.3390/cancers16061137 | PMID 38539472 Get It

Background: Bimiralisib is a pan-PI3K/mTOR inhibitor demonstrating antitumor efficacy in preclinical models. The objectives of this study were to identify a maximum tolerated dose (MTD), pharmacokinetics (PK), a dosing schedule, and adverse events (AEs) in patients with advanced solid tumors. Patients and Methods: Patients received oral bimiralisib to determine the MTD of one continuous (once daily) and two intermittent schedules (A: Days 1, 2 weekly; B: Days 1, 4 weekly) until progression or unacceptable AEs occurred. Results: The MTD for the continuous schedule was 80 mg, with grade three fatigue as the dose-limiting toxicity (DLT). No MTD was reached with intermittent schedules, with only one DLT in schedule B. PK analysis suggested that 140 mg (schedule A) was within the biologically active dose range and was selected for further exploration. The most frequent treatment-emergent AEs were hyperglycemia (76.2%) in the continuous schedule, and nausea (56–62.5%) in schedules A and B. The most frequent treatment-emergent > grade three AE for all schedules combined was hyperglycemia (28.6%, continuous schedule; 12.0%, schedule A; 12.5%, schedule B). There was one partial response in a head and neck squamous cancer patient with a NOTCH1T1997M mutation. Conclusions: Bimiralisib demonstrated a manageable AE profile consistent with this compound class. Intermittent schedules had fewer > grade three AEs, while also maintaining favorable PK profiles. Intermittent schedule A is proposed for further development in biomarker-selected patient populations.
Advanced Imaging in the Diagnosis and Response Assessment of High-Grade Glioma: AJR Expert Panel Narrative Review
Hu, Leland , Smits, Marion , Sundgren, Pia C. , Smits, Marion , Kaufmann, Timothy J. , Knutsson, Linda , Rapalino, Otto , Galldiks, Norbert , Cha, Soonmee

American Journal of Roentgenology | March 13, 2024 | Volume: 224 | Issue: 1 | Pages: No page available

10.2214/ajr.23.30612 | PMID 38477525 Get It

Identification of Nonfunctional Alternatively Spliced Isoforms of STING in Human Acute Myeloid Leukemia
Boda, Akash R. , Liu, Arthur , Castro-Pando, Susana , Whitfield, Benjamin T. , Molldrem, Jeffrey J. , Alatrash, Gheath , Francesco, Maria Emilia Di , Jones, Philip , Ager, Casey R. , Curran, Michael A. , Liu, Arthur J , Al-Atrash, Gheath , Di Francesco, Maria Emilia , Curran, Michael A , Molldrem, Jeffrey J

Cancer Research Communications | March 13, 2024 | Volume: 4 | Issue: 3 | Pages: 911-918

10.1158/2767-9764.crc-24-0095 | PMID 38477596 Get It

Abstract Lack of robust activation of Stimulator of Interferon Genes (STING) pathway and subsequent induction of type I IFN responses is considered a barrier to antitumor immunity in acute myeloid leukemia (AML). Using common human AML cell lines as in vitro tools to evaluate the efficacy of novel STING agonists, we found most AML lines to be poor producers of IFNs upon exposure to extremely potent agonists, suggesting cell-intrinsic suppression of STING signaling may occur. We observed unexpected patterns of response that did not correlate with levels of STING pathway components or of known enzymes associated with resistance. To identify a genetic basis for these observations, we cloned and sequenced STING from the cDNA of human AML cell lines and found both frequent mutations and deviations from normal RNA splicing. We identified two novel spliced isoforms of STING in these lines and validated their expression in primary human AML samples. When transduced into reporter cells, these novel STING isoforms exhibited complete insensitivity to agonist stimulation. These observations identify alternative splicing as a mechanism of STING pathway suppression and suggest that most AML silences the STING pathway through direct modification rather than through engagement of external inhibitory factors. Significance: We find that AML acquires resistance to innate immune activation via the STING pathway through aberrant splicing of the STING transcript including two novel forms described herein that act as dominant negatives. These data broaden understanding of how cancers evolve STING resistance, and suggest that the AML tumor microenvironment, not the cancer cell, should be the target of therapeutic interventions to activate STING.